Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
lunresertib (RP-6306)
i
Other names:
RP-6306, RP 6306, Manchester, RP6306
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(4)
News
Trials
Company:
Debiopharm, Repare Therap
Drug class:
PKMYT1 inhibitor
Related drugs:
‹
SGR-3515 (0)
SGR-3515 (0)
›
Associations
(4)
News
Trials
VERI cancer hierarchy
Reset Filters
CCNE1 amplification
Solid Tumor
CCNE1 amplification
Solid Tumor
RP-6306
Sensitive: C2 – Inclusion Criteria
RP-6306
Sensitive
:
C2
RP-6306
Sensitive: C2 – Inclusion Criteria
RP-6306
Sensitive
:
C2
CCNE1 amplification
Ovarian Cancer
CCNE1 amplification
Ovarian Cancer
RP-6306
Sensitive: C2 – Inclusion Criteria
RP-6306
Sensitive
:
C2
RP-6306
Sensitive: C2 – Inclusion Criteria
RP-6306
Sensitive
:
C2
FBXW7 mutation
Solid Tumor
FBXW7 mutation
Solid Tumor
RP-6306
Sensitive: D – Preclinical
RP-6306
Sensitive
:
D
RP-6306
Sensitive: D – Preclinical
RP-6306
Sensitive
:
D
CCNE1 amplification
Hepatocellular Cancer
CCNE1 amplification
Hepatocellular Cancer
RP-6306
Sensitive: D – Preclinical
RP-6306
Sensitive
:
D
RP-6306
Sensitive: D – Preclinical
RP-6306
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.